JP6931042B2 - 甲状腺ベータアゴニストの使用 - Google Patents

甲状腺ベータアゴニストの使用 Download PDF

Info

Publication number
JP6931042B2
JP6931042B2 JP2019507069A JP2019507069A JP6931042B2 JP 6931042 B2 JP6931042 B2 JP 6931042B2 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 6931042 B2 JP6931042 B2 JP 6931042B2
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
substituted
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019507069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515033A (ja
JP2019515033A5 (https=
Inventor
ジアン，ホンジエン
リアン，ブライアン
ハンレー，ロシェル
ディナーマン，ミシャ
エリオン，マーク
ボワイエ，サージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of JP2019515033A publication Critical patent/JP2019515033A/ja
Publication of JP2019515033A5 publication Critical patent/JP2019515033A5/ja
Application granted granted Critical
Publication of JP6931042B2 publication Critical patent/JP6931042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019507069A 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用 Active JP6931042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (3)

Publication Number Publication Date
JP2019515033A JP2019515033A (ja) 2019-06-06
JP2019515033A5 JP2019515033A5 (https=) 2020-06-11
JP6931042B2 true JP6931042B2 (ja) 2021-09-01

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019507069A Active JP6931042B2 (ja) 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用

Country Status (10)

Country Link
US (3) US11351183B2 (https=)
EP (1) EP3445373B1 (https=)
JP (1) JP6931042B2 (https=)
KR (1) KR102407059B1 (https=)
AU (1) AU2017252126B2 (https=)
BR (1) BR112018071586A2 (https=)
CA (1) CA3021681C (https=)
ES (1) ES2992773T3 (https=)
MX (1) MX385085B (https=)
WO (1) WO2017185087A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA2638753A1 (en) 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
EP1987827A1 (en) 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
CN103649103A (zh) 2011-06-21 2014-03-19 阿尔尼拉姆医药品有限公司 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3259246B1 (en) 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
EP3423379B1 (en) 2016-02-29 2020-04-01 Philip Morris Products S.a.s. Hinge-lid container and blank
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
CA3021677C (en) 2016-04-22 2024-11-12 Viking Therapeutics, Inc. USE OF BETA-AGONISTS OF THYROID HORMONES
CN109475121B (zh) 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物

Also Published As

Publication number Publication date
MX2018012900A (es) 2019-07-01
BR112018071586A2 (pt) 2019-02-12
WO2017185087A1 (en) 2017-10-26
KR20190039027A (ko) 2019-04-10
KR102407059B1 (ko) 2022-06-10
US20220257618A1 (en) 2022-08-18
CA3021681C (en) 2024-09-24
JP2019515033A (ja) 2019-06-06
EP3445373B1 (en) 2024-08-21
US20250000880A1 (en) 2025-01-02
US11951114B2 (en) 2024-04-09
CA3021681A1 (en) 2017-10-26
AU2017252126B2 (en) 2023-02-09
EP3445373A4 (en) 2019-12-18
AU2017252126A1 (en) 2018-11-08
ES2992773T3 (en) 2024-12-18
EP3445373A1 (en) 2019-02-27
US20190321379A1 (en) 2019-10-24
MX385085B (es) 2025-03-14
US11351183B2 (en) 2022-06-07
US12440502B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
US12440502B2 (en) Use of thyroid beta-agonists
AU2023202321B2 (en) Use of thyroid beta-agonists
WO2020051322A1 (en) Methods of treating cytokine release syndrome
JP6010196B2 (ja) オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法
JP2022515293A (ja) クロモリンエステルおよびそれらの使用
JP7019585B2 (ja) 核酸プロドラッグ
JP2020536853A (ja) 転写因子ｓａｌｌ４の小分子阻害およびその使用
HK40064933A (en) Use of thyroid beta-agonists
HK40013781A (en) Use of thyroid beta-agonists
HK40013781B (zh) 甲状腺β-激动剂的应用
HK40007271A (en) Use of thyroid beta-agonists
CN108289899A (zh) 采用葡萄糖生成的抑制剂的联合疗法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210812

R150 Certificate of patent or registration of utility model

Ref document number: 6931042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250